Ionis expands eplontersen deal with AstraZeneca

31 July 2023

Shares of Ionis Pharmaceuticals (Nasdaq: IONS) closed up 3.3% at $39.79 on Friday, after the US RNA-targeted drug developer revealed it has expanded its existing collaboration with AstraZeneca (LSE: AZN) to include exclusive rights for the UK pharma major to commercialize eplontersen in Latin America.

Ionis previously granted AstraZeneca exclusive rights to commercialize eplontersen in all other countries outside the USA in December 2021, in a deal worth a potential $3.6 billion. Ionis and AstraZeneca will continue to jointly develop and commercialize eplontersen in the USA.

The companies are successfully advancing eplontersen by combining Ionis' industry-leading expertise in RNA-targeted therapeutics and deep knowledge of transthyretin amyloidosis (ATTR) with AstraZeneca's global cardiovascular commercial capabilities. In April this year, the companies announced positive results from the NEURO-TTRansform Phase III trial in hereditary transthyretin-mediated amyloid polyneuropathy (ATTRv-PN) testing eplontersen.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK